数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
研究问题
Alzheimer’s disease (AD) is primarily characterized by progressive cognitive dysfunction and behavioral impairments, which severely affect the quality of daily life for patients and impose a heavy social caregiving burden [1, 2].
方法
（全文无独立方法节，正文亦未给出可抽取的实验动作句）
核心结论
Initially, a comprehensive domain-wide search was performed using the following query string: (“Alzheimer disease” OR “AD”) AND (“amyloid β-protein” OR “amyloid-beta” OR “Aβ”) AND (“antibody” OR “monoclonal antibody” OR “mAb”) AND (“engineering” OR “modification” OR “design”).；Subsequently, a refined, strategy-specific search was implemented with the following dedicated queries: (1) BBB-shuttling bispecific antibodies: (“bispecific antibody” OR “brain shuttle”) AND (“anti-Aβ” OR “amyloid β-protein” OR “amyloid-beta” OR “Aβ”) AND (“transferrin receptor” OR “TfR” OR “insulin receptor” OR “INSR” OR “CD98hc”); (2) Glycosylation engineering: (“glycosylation” OR “glycoengineering” OR “Fc glycan”) AND (“anti-Aβ” OR “amyloid β-protein” OR “amyloid-beta” OR “Aβ”) AND (“antibody” OR “monoclonal antibody” OR “mAb”); (3) Antibody-drug conjugates: (“antibody-drug conjugate” OR “ADC”) AND (“anti-Aβ”… ‖ 结论：Only by overcoming these unique translational hurdles can next-generation engineered anti-Aβ biologics achieve robust clinical application.
局限
全文未设独立 limitations 节；结构上为综述/二次研究，因果推断强度受限。
对本项目的价值
★★☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。
全文来源
PMC JATS 全文（正文 45,249 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Advances in modified anti-Aβ antibodies for the treatment of Alzheimer's disease.
- 期刊与标识：BMC Med · PMID 42934641 · DOI 10.1186/s12916-026-05088-0**
C 级证据分级：C 级（预印本 / 观点评论，非原始研究）
本文属观点/评论类文献，不是原始研究。其论点依赖于作者对既有证据的梳理与判断，不构成新的实验证据。本站标注 C 级即为此意——阅读时请把它当作「领域内的思考框架」，而非「研究发现」。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。